Therapeutic

Epigenomics

Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics

Publication Date	March 2007
Publisher	BCC Research
Product Type	Report
Pages	267
ISBN Number	not applicable
Product Code	BCC00049

Price

£3,205.00
approximately: $4,853 | €3,577

print

Order above formats by FAX

BCC's goal for this study was to determine the current status of emerging commercial epigenomics technologies and products and assess their worldwide growth potential over a 5-year period from 2007 to 2012. We were particularly interested in characterizing the epigenomic research tools market, a key enabling technology for other epigenomics markets. Of particular interest were the larger markets for DNA methylation-based diagnostics and epigenetic drugs for cancer.

Our key objective was to present a comprehensive discussion of where the state-of-the-art is in epigenomics technologies and the current and future commercial potential for the key market segments.

Scope Of Study

This report contains:

The major epigenomics technologies and developments that are likely to become commercialized within the next five years
Provides detailed market information for the global epigenomics market including historical data, current information, and projections to 2012
Offers a focus on particular applications of epigenomics, including research tools, diagnostics, drugs, and cloning/tissue engineering
Discusses the market in terms of important medical applications such as biomarkers, cancer therapy, and reproductive technology
Offers a detailed review of important patents and technologies
Profiles the most competitive businesses in the industry

Report Highlights

The global market for epigenomics was $161.8 million in 2005 and $263.2 million in 2006. The market will cross $385 million by 2007 and at a compound annual growth rate (CAGR) of 60.4% will reach nearly $4.1 billion by 2012.

Drug applications for epigenetics are by far the largest sector of the market. These drugs will hold 61% of the total global market in 2007 and will grow to over a 65% market share by 2012.

Epigenetic diagnostics has the most potential for growth through the forecast period. In 2006 and 2007 its applications were negligible, but by 2012 this booming sector will be worth over $947 million.

Introduction
- Study Goals And Objectives
- Reasons For Doing The Study
- Contribution Of The Study And For Whom
- Scope And Format
- Methodology
- Analyst Credentials
- Related Bcc Publications
- Bcc Online Services
- Disclaimer
Summary
- Summary Table: Global Value Of Epigenomics Products By Market Segment, Through 2012 ($ Millions)
- Summary Figure: Global Value Of Epigenomics Products By Market Segment, 2005-2012 ($ Millions)
Overview
- Introduction
- The New Paradigm Of Epigenomics
- How Epigenomics Fits Within The Genomics Field
- Elements Of The Epigenome Covered In This Report
- Market Potential Of Epigenomics
- Key Epigenomics Products
  - Research Tools And Reagents
  - Diagnostics
  - Drugs
- Driving Forces For Growth In Epigenomics
- Importance Of Epigenetic Technology
- Life Cycle Status Of Epigenomics Technologies
- Historical Background
- The Epigenomics Industry
  - The Epigenomics Industry (Continued)
Epigenetic Technology
- Introduction
- Two Main Epigenomic Analysis Technologies
  - Status Of Dna And Histone Analysis Technologies
- Dna And Histone Analysis Workflow
- Dna Methylation
  - Methylated Cytosine-A Fifth Base
  - Biological Role Of Dna Methylation
  - Dna Methyltransferase Enzymes
  - Cpg Islands
- Histone Methylation And Acetylation
  - Histones
  - Histone Acetylation And Methylation Enzymes
    - Histone Acetyl Transferases (Hat Enzymes)
    - Histone Deacetylases (Hdac Enzymes)
    - Histone Methyltransferases And Demethylases
- Inappropriate Methylation And Acetylation
Epigenomic Analysis Technologies
- Role Of Epigenomic Research Tools
- Dna Methylation Research Tools
- Dna Methylation Analysis Workflow
  - Analysis Types By Workflow
- Dna Methylation Analysis: Upstream Technologies
  - Restriction Enzyme-Based Methods
  - Bisulfite-Based Methods
    - Bisulfite-Based Methods (Continued)
    - Analysis Of Low Complexity Dna-A Unique Challenge For Bisulfite Methods
  - Antibody-Based Methods
  - Challenge Of High Background Methylated Dna
- Dna Methylation Analysis: Downstream Technologies
- Genome Wide Dna Methylation Analysis
  - Genome Wide Dna (Continued)
- High Throughput Platforms
- Histone Epigenomic Analysis Technologies
  - Chromatin Immunoprecipitation
  - Chip-On-Chip
- Microarrays
  - Feature Density
  - Resolution
  - Genome Content
- Serial Analysis Of Gene Expression
- Antibodies
- Alternatives To Antibodies In Upstream Step
  - Dna Adenine Methyltransferase Identification (Dam Id)
    - Dna Adenine Methyltransferase (Continued)
Dna Methylation Biomarkers
- From Analysis To Biomarkers
- Opportunities For Biotechnology Companies In Diagnostics
- What Is A Biomarker?
- Dna Methylation As A Cancer Biomarker
  - Dna Methylation In Cancer Etiology
    - Cell Cycle Control
    - Cell Invasion And Adhesion
    - Dna Damage Repair
    - Growth Factor Response
    - Regulation Of Apoptosis
    - Hormonal Response
    - Cytokine Signaling
  - Molecular Biomarker Technology Comparison
    - Occurrence Within The Genome
    - Inheritance In Progenitor Cells
    - Dna Base Mutation
    - Binary Signal
    - Presence Of Background Signal
    - Stable Change In Biomarker Status
    - Stability Of Sample Material
    - Detection Of First Hit
    - Occurrence In Early Or Pre-Cancers
    - Tissue Sample Range
    - Test Complexity
- Assessment Of Dna Methylation Biomarker Competitive Position
- Epigenetic Biomarker Cancer Genes
- Epigenetic Biomarkers For Non-Cancer Diseases
- Biomarker Discovery Process
- Methylation Biomarker Discovery Technologies
  - Genome-Wide Scanning To Hunt For Biomarkers
- Large Scale Regional Epigenomics Projects
  - Europe
  - United States
  - Asia
- Human Epigenome Project Will Aid In The Discovery Of New Methylation Markers
- Case Study: From Research Tools To Biomarkers
  - Case Study (Continued)
- Development Stages For An In Vitro Diagnostic
  - Phase 1: Biomarker Discovery
  - Phase 2: Biomarker Validation
  - Phase 3: Formal Kit Development
  - Phase 4: Clinical Validation
- Types Of Cancer Methylation Markers
- Future Status Of Dna Methylation Biomarkers
Epigenetic Cancer Therapies
- Introduction
- Epigenetics In Tumorigenesis
- Epigenetic Drug Targets
- Histone Methylation And Acetylation Enzyme Drug Targets
- Histone Deacetylace Inhibitors
- Hdac Enzymes As Drug Targets
- Hdac Inhibitor Drug Classes
  - Hydroxamates
  - Aliphatic Acids
  - Cyclic Tetrapeptides
  - Benzamides
- Key Hdac Inhibitor Technology Trends
  - Enzyme Selectivity
    - Enzyme Selectivity (Continued)
  - Potency
  - Improvements In Drug-Like Properties
- Selective Hdac Compounds Can Provide Competitive Advantage
  - Chemical Design Is The Key To Selectivity
- Hdac Inhibitors In Combination Therapies
  - Hdac Inhibitors In (Continued)
  - Hdac Inhibitors In (Continued)
- Hdac Inhibitors As Therapies For Non-Cancer Diseases
  - Cardiac Disease
  - Dermatological Disorders
  - Parasitic Diseases
  - Neurodegenerative Diseases
  - Diabetes
  - Inflammatory Diseases
- Dna Methyltransferase Inhibitors (Dnmt)
  - Nucleoside Analogues
  - Non-Nucleoside Analogues
  - Antisense Oligonucleotides
- Future Challenges For Epigenetic Drug Development
Epigenetics Assisted Reproductive Technologies
- Somatic Cell Nuclear Transfer
- Applications Of Epigenomics In Cloning
  - Reprogramming Factors
  - Cellular Identification And Quality Control Assays
    - Cellular Identification (Continued)
Market Growth Driving Forces
- Introduction
- Key Growth Drivers
  - Development Of Novel Epigenomics Research Tools
  - Creation Of Epigenetic Maps
  - Scope Of Epigenetic Analysis
  - Need For Early Cancer Detection
  - Need For Better Cancer Therapies
  - Growth In Life Science Research Budgets
  - Personalized Medicine Trends
  - Research In Epigenetic Processes
Epigenomic Research Tools Markets
- Products Within Research Tools
  - Epigenomic Kits
  - Reagents
  - Microarrays
- Global Sales By Technology
- Global Sales By Product
- Epigenomic Kit Sales By Technology
- Dna Methylation Analysis Kit Market
  - Dna Methylation (Continued)
  - Histone Analysis Kit Market
- Microarray Market
  - Microarrays As Downstream Analysis Tool
    - Microarray Differentiation
    - Microarray (Continued)
  - Microarray Analysis Platforms In The Clinic
    - Microarray Analysis (Continued)
  - Future Market Position Of Microarrays
  - Epigenomic Microarray Market
- Reagents Market
  - Reagents Market (Continued)
Epigenetic Biomarker And Diagnostics Markets
- Overview Of Cancer Diagnostics Market
- Cancer Molecular Diagnostics Growth Drivers
- Methylation Biomarkers Clinical Development Status
  - Cancer Diagnostic Market Segments
- Attractive Cancer Indications For Screening Markets
- Sensitivity And Specificity
- Status Of Diagnostics Tests For Selected Cancer Indications
  - Colorectal Cancer
    - Colorectal Cancer Screening Tests
    - Dna-Based Colorectal Screening Tests
    - Epigenetics-Based Colorectal Screening Tests
    - Colorectal Cancer Non-Screening Tests
  - Bladder Cancer
  - Breast Cancer
    - Screening For Breast Cancer
    - Relapse Risk Prediction
    - Therapy Prediction
  - Prostate Cancer
  - Lung Cancer
  - Ovarian Cancer
  - Cervical Cancer
  - Pancreatic Cancer
  - Gastric Cancer
  - Pediatric Cancers
- Personalized Treatment Epigenetic-Based Tests
- Key Clinical Requirements For An Epigenetic-Based Diagnostics Test
- Available Market For Cancer Molecular Diagnostic Tests
  - Available Market For (Continued)
- Aging Populations Contribute To Diagnostics Market Potential
- Dna Methylation Diagnostics Pipeline
  - Screening Tests
    - Prostate Cancer Screening Tests
    - Colorectal Cancer Screening Tests
    - Breast Cancer Screening Tests
    - Lung Cancer Screening Tests
    - Bladder Cancer Screening Tests
  - Monitoring, Classification, And Pharmacodiagnostic Tests
    - Breast Cancer Classification Tests
    - Prostate Cancer Diagnostics Tests
    - Bladder Cancer Monitoring Tests.
    - Other Non-Screening Tests
- Epigenetics Based Diagnostics Kits Market Size
- Epigenetic Diagnostics Kits Market By Technology
  - Epigenetic Diagnostics (Continued)
Markets For Epigenetic Drugs
- Overview
- The Cancer Drug Market
- Targeted Therapeutics
- Cancer Drug Market Growth Driving Forces
  - Cancer Drug (Continued)
- Epigenetic-Based Drugs As Cancer Therapies
- Proof Of Principle Of Epigenetic Drugs Established
- Epigenetic Therapies Beyond Cancer
- Epigenetic Drug Market Forecast
- Initial Focus On Hematological Cancers
- Market Size For Hematological Cancer Drugs
  - Market Size (Continued)
- Hdac Inhibitors Markets
  - Strategic Opportunities In Hdac Inhibitors
  - Hdac Inhibitors In Development And Clinical Trials
    - Zolinza
    - PXD-101
    - NVP-LAQ824
    - Bacacea, Avugane, Savacol
    - Romidepsin
    - MS-275
    - CI 994
    - MGCD0103
    - PCI-24781
    - SRT-501
  - HDAC Inhibitor Drug Market Size By Indication
  - HDAC Inhibitor Market Size By Technology
- DNMT Inhibitors Market
  - DNMT Inhibitors In Clinical Trials
    - Nucleoside Analogues
    - 5-azacytidine (Vidaza)
    - 5-aza-2'-deoxycitidine (Decitabine, Dacogen)
    - Zebularine
    - DHAC (Dihydro-5-azacytidine)
    - Non-Nucleoside Analogues
    - MG98
    - Hydralazine
    - Preclinical Non-Nucleosides
  - FDA-Approved DNMT Inhibitors
  - Market Size For DNMT Inhibitors
  - Alternative Demethylation Therapeutic Approaches
- Cloning And Tissue Engineering Markets
Competitive Dynamics
- Research Tools
- Diagnostics
- Epigenetic Drugs
Patents
- Research Tools
- Biomarkers And Diagnostics
- Pharmaceuticals
Company Profiles
- Abbott Laboratories
- Abcam Plc.
- Active Motif
- Affymetrix
- Agilent Technologies, Inc.
- Applied Biosystems
- Aviva Systems Biology
- Bayer Ag
- Bioserve Biotechnologies, Ltd.
- Biovision
- Cellartis Ab
- Cellcentric Ltd.
- Chipscreen Biosciences Ltd.
- Chroma Therapeutics
- Curagen
- Epigenomics Ag
  - Epigenomics Ag (Continued)
- Epigentek
- Epiontis Gmbh
- Elixir Pharmaceuticals, Inc.
- Entremed, Inc.
- Envivo Pharmaceuticals
- Es Cell International Pte Ltd
- Exonhit Therapeutics Sa
- F. Hoffmann-La Roche, Ltd.
- Genpathway, Inc.
- Gilead Sciences (Myogen)
- Gloucester Pharmaceuticals
- Huya Bioscience International
- Illumina, Inc.
- Kalypsys, Inc.
- Karus Therapeutic Ltd
- Leo Pharma
- Merck & Co. Inc.
- Methylgene
- Mgi Pharma, Inc.
  - Mgi Pharma, Inc. (Continued)
- Millipore (Chemicon/Upstate)
- Nimblegen Systems, Inc.
- Novartis
  - Oncomethylome Sciences S.A.
    - Biomarker Identification And Development Partners
    - Kit Development, Regulatory Review, And Mass Market Of Kits
- Orion Genomics
  - Orion Genomics (Continued)
- Panomics, Inc.
- Pharmacyclics
- Pharmion Corporation
- Quiagen Gmbh
- Rubicon Genomics
- S*Bio Pte Ltd1
- Schering Ag
- Schering Plough Corporation
- Sequenom
- Seqwright
- Sirtris Pharmaceuticals
- Taiho Pharmaceuticals
- Takeda Pharmaceutical Company Limited
- Topotarget A/S
- Veridex Llc
- Zymo Research
List Of Tables
- Summary Table:Global Value Of Epigenomics Products By Market Segment, Through 2012 ($ Millions)
- Table 1 Genomics Platforms
- Table 2 Elements Of The Epigenome Covered In This Report
- Table 3 Global Value Of Epigenomics Products By Market Segment, Through 2012 ($ Millions)
- Table 4 Historical Overview Of Epigenetics
- Table 5 Epigenomics Industry
- Table 6 Two Types Of Epigenomic Analysis Technologies
- Table 7 Status Of Dna And Histone Analysis Technologies
- Table 8 Biological Roles Of Dna Methylation
- Table 9 Cpg Islands: Subject To Dna Methylation
- Table 10 Hdac Enzymes Classes
- Table 11 Mechanisms For Inappropriate Methylation And Acetylation
- Table 12 Dna Methylation Analysis Assays
- Table 13 Examples Of Dna Methylation Assays
- Table 14 Comparison Of Upstream Epigenomic Recognition Technologies
- Table 15 Dna Methylation Analysis Techniques By Genome Resolution
- Table 16 Chip Assays
- Table 17 Technologies For Mapping Genomic Location Of Chromatin Proteins And Enzymes
- Table 18 Microarray Genome Content
- Table 19 Platforms For High Density Oligonucleotide Epigenetics Arrays
- Table 20 Biological Rationale For Dna Methylation Cancer Biomarkers
- Table 21 Cancer-Related Cell Pathways And Genes Affected By Hyper-Methylation
- Table 22 Cancer-Related Epigenetic Changes
- Table 23 Comparison Of Key Cancer Biomarker Technology Platforms
- Table 24 Published Dna Methylation Biomarker Genes For Cancers
- Table 25 Differentially Methylated Genes In Neurologic And Cardiovascular Disorders
- Table 26 Dna Methylation Analysis Technologies In Biomarker Discovery
- Table 27 Regional Epigenomics Initiatives
- Table 28 Methyl Variable Positions - Mvps
- Table 29 Human Epigenome Project: Methyl Variable Position Analysis Objectives
- Table 30 Technical Hurdles For Development Of Methylation Epigenetic Cancer Biomarkers
- Table 31 Epigenetic Genes Altered In Human Cancers
- Table 32 Status Of Epigenetic Enzymes That Target Histones
- Table 33 Hdac Inhibitor Classes And Relative Potency
- Table 34 Ms-275, A Benzamide Class Hdac Inhibitor
- Table 35 Key Hdac Inhibitor Drug Trends
- Table 36 Hdac Inhibitor Class I And Ii Selectivity (Ic50 Ratio)
- Table 37 Hdac Inhibitor Drug Companions
- Table 38 Future Challenges For Epigenetic Drug Development
- Table 39 Technology Opportunities In Somatic Cell Nuclear Transfer
- Table 40 Epigenetic Alterations In Assisted Reproductive Disorders
- Table 41 Growth In Scientific Publications Related To Epigenetics
- Table 42 Primary Forces Driving Epigenomics Products Growth
- Table 43 Global Market Forecast For Epigenomics Research Tool Kits By Type Through 2012 ($ Million)
- Table 44 Global Market Forecast For Epigenomic Analysis Research Tools By Technology Through 2012 ($ Millions)
- Table 45 Global Market Forecast For Epigenetic Analysis Kits By Technology Through 2012 ($ Millions)
- Table 46 Global Market Forecast For Dna Methylation Research Tool Kits By Analysis Objective Through 2012 ($ Millions)
- Table 47 Global Market Forecast For Dna Methylation Research Tools Kits By Technology Through 2012 ($ Millions)
- Table 48 Global Market Forecast For Dna Methylation Single Loci Research Tools Kits By Technology Through 2012 ($ Millions)
- Table 49 Global Market Forecast For Dna Methylation Genome-Wide Research Tools Kits By Technology Through 2012 ($ Millions)
- Table 50 Global Market Forecast For Value Of Histone Analysis Kits By Technology Through 2012 ($ Millions)
- Table 51 Microarray Probes
- Table 52 Clinical Status Of Microarray Platforms
- Table 53 Global Value Of Epigenomic Microarrays By Market Through 2012 ($ Millions)
- Table 54 Global Value Of Epigenomic Research Tools Microarrays By Analysis Through 2012 ($ Millions)
- Table 55 Global Value Of Diagnostic Microarrays By Market Through 2012 ($ Millions)
- Table 56 Global Value Of Epigenomic Reagents By Market Through 2012 ($ Millions)
- Table 57 Global Value Of Research Tools Epigenomic Reagents By Technology Through 2012 ($ Millions)
- Table 58 Value Of Global Molecular Diagnostics Markets By Segment Through 2012 ($ Millions)
- Table 59 Targeted Therapy Cancer Drug Compounds In Development
- Table 60 Development Status Of Selected Methylation Biomarkers By Cancer Type
- Table 61 Current Screening And Diagnostics Tests For Colorectal Cancer
- Table 62 Accuracy Of Existing Colorectal Screening Tests
- Table 63 Ovarian Cancer Potential Screening Tests
- Table 64 Requirements For An Epigenetics Bisulfite Diagnostic Kit
- Table 65 Global 2007 Potential Available Market For Cancer Molecular Diagnostic Test Kits By Market Segment ($ Millions)
- Table 66 Global 2007 Potential Available Market For Cancer Molecular Diagnostics Test Kits By Indication ($ Millions)
- Table 67 Cancer Incidence And Estimated Treatment Decisions, 2006
- Table 68 Breast Cancer Diagnostics Product Segments
- Table 69 Projected Increase In Age 65+ Population By Region
- Table 70 Pipeline For Dna Methylation Diagnostics Tests
- Table 71 Global Value Of Epigenetic Diagnostic Kits By Market Through 2012 ($ Millions)
- Table 72 Global Value Of Epigenetic Diagnostic Kits By Indication Through 2012 ($ Millions)
- Table 73 2012 Global Value Of Epigenetic Diagnostic Kits By Indication And Segment ($ Millions)
- Table 74 Global Value Of Epigenetic Diagnostic Kits By Technology Through 2012 ($ Millions)
- Table 75 Global Market Forecast For Selected Cancer Drugs By, Through 2012 ($ Millions)
- Table 76 Global Market Forecast For Epigenetic Drugs By Indication, Through 2012 ($ Millions)
- Table 77 Global Market Forecast For Epigenetic Drugs By Class, Through 2012 ($ Millions)
- Table 78 Overview Of Major Hematological Malignancies
- Table 79 Global Market Forecast Of Hematological Cancer Drugs By Indication Through 2012 ($ Millions)
- Table 80 Comparison Of Three New Mds Drugs
- Table 81 Summary Of Hdac Inhibitor Strategic Opportunities For Cancer Treatment
- Table 82 Hdac Inhibitor Drug Candidates In Clinical Trials
- Table 83 Pxd-101 Clinical Trials Status
- Table 84 Romidepsin Clinical Trials Status
- Table 85 Mbcd0103 Inhibits Selected Hdac Enzymes
- Table 86 Global Market Forecast For Hdac Inhibitor Drugs By Indication, Through 2012 ($ Millions)
- Table 87 Global Value Of Hdac Inhibitor Drugs By Technology Through 2012 ($ Millions)
- Table 88 Dnmt Inhibitors In Clinical Trials And Under Development
- Table 89 Fda Approved Dnmt Inhibitor Drugs
- Table 90 Global Value Of Dnmt Inhibitor Drugs By Indication Through 2012 ($ Millions)
- Table 91 Global Value Of Dnmt Inhibitor Drugs By Technology Through 2012 ($ Millions)
- Table 92 Global Value Of Cloning And Tissue Engineering Epigenetic Kits Through 2012 ($ Millions)
- Table 93 Epigenomic Research Tools Suppliers
- Table 94 Strategic Alliance Status For Biotechnology Epigenetics Diagnostics Firms
- Table 95 Competitive Landscape For Molecular Diagnostics Technologies
- Table 96 Competitive Landscape For Epigenetic Drug Companies
- Table 97 Patents And Patent Application Status Of Epigenomics Ag Research Tools
- Table 98 Patent Status For Biotechnology Diagnostics Companies
- Table 99 Hdac Inhibitor Patent Claims: 2004-2006
- Table 100 Curagen Strategic Alliances
- Table 101 Methylgene Epigenetic Product Pipeline
- Table 102 Pharmion Epigenetic Drug Combination Therapies In Clinical Trials
- Table 103 Potential Pharmion Intra-Portfolio Drug Combinations
- Table 104 Topotarget's Hdac Inhibitor Patent Portfolio
List Of Figures
- Summary Figure: Global Value Of Epigenomics Products By Market Segment, 2005-2012 ($ Millions)
- Figure 1 Epigenomics: A New Paradigm
- Figure 2 Epigenetic Processes Can Generate Abnormal Cells During Cell Development
- Figure 3 Upstream And Downstream Steps In Epigenetic Analysis
- Figure 4 Epigenetic Changes To Dna Affect Gene Expression
- Figure 5 Histone Tail Regions Modified By Hat And Hdac
- Figure 6 Histone Acetylation And Methylation Enzymes
- Figure 7 Methylated Dna Analysis Workflow
- Figure 8 Analysis Of Dna Methylation By Restriction Enzymes
- Figure 9 Bisulfite Conversion Of Dna
- Figure 10 Chip-On-Chip Procedure
- Figure 11 Microarray Feature Density
- Figure 12 Microarray Resolution
- Figure 13 Histone Deacetylase Reaction
- Figure 14 Trichostatin A, A Hydroxamate Class Hdac Inhibitor
- Figure 15 Phenylbutyric Acid, An Aliphatic Acid Class Hdac Inhibitor
- Figure 16 Apicidin A, A Cyclic Tetrapeptide Class Hdac Inhibitor
- Figure 17 Disease Hdac Isoform Profile
- Figure 18 Structural Components Motifs Of Hdac Inhibitors
- Figure 19 Lead Dnmt Inhibitor Compounds
- Figure 20 Dnmt Inhibitors And Mode Of Action
- Figure 21 Somatic Cell Nuclear Transfer
- Figure 22 Epigenetic Programming Of Stem Cells
- Figure 23 Microarrays Enhance Multiplex Capabilities Of Epigenetics Assays
- Figure 24 Cancer Screening Opportunity Matrix For Epigenetic Tests In Development
- Figure 25 New Epigenetic Screening Paradigm
- Figure 26 Sensitivity And Specificity

Therapeutic

Epigenomics

Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics

Price

Summary

Scope Of Study

Report Highlights

Contents

Bookmark this Product